Company Overview
Snapshot
Founded in July 2021 by Anat Horev and Bilha Cahana, Vflow21 operates with 1–10 employees. The company has secured funding across two rounds, with Sanara Capital participating in its April 2025 funding round.
Business overview
Vflow21 is a medical device company specializing in innovative solutions for neurovascular diseases. The company's core focus is on developing treatments for conditions such as Idiopathic Intracranial Hypertension and Tinnitus. Operating within the Health Tech & Life Sciences sector, Vflow21 serves the healthcare industry, particularly providers, with its medical devices and therapeutic solutions.
Log in to access full profile ›Company Intelligence Q&A
- When was Vflow21 founded and by whom?
- Vflow21 was founded in July 2021 by co-founders Anat Horev and Bilha Cahana.
- What is Vflow21's primary focus in the medical device sector?
- Vflow21 develops innovative solutions for neurovascular diseases, with a specific focus on Idiopathic Intracranial Hypertension and Tinnitus Treatment.
- Did Vflow21 receive any grants from governmental bodies?
- In June 2023, Vflow21 received funding from the Israel Innovation Authority.
- What is the current product stage of Vflow21?
- Vflow21's products are currently in the Research & Development (R&D) stage, focusing on developing innovative solutions for neurovascular diseases.